Agios Presents Updated PYRUKYND® (mitapivat) Data Highlighting Long ...
Agios Pharmaceuticals reported new Phase 2 study data on PYRUKYND® for α- and β-thalassemia, showing durable improvements in hemoglobin and hemolysis markers. The drug was well-tolerated, with a consistent safety profile. Agios is enrolling for Phase 3 trials and highlighted the need for new thalassemia therapies at the ASH meeting.
Reference News
Agios Presents Updated PYRUKYND® (mitapivat) Data Highlighting Long ...
Agios Pharmaceuticals reported new Phase 2 study data on PYRUKYND® for α- and β-thalassemia, showing durable improvements in hemoglobin and hemolysis markers. The drug was well-tolerated, with a consistent safety profile. Agios is enrolling for Phase 3 trials and highlighted the need for new thalassemia therapies at the ASH meeting.